Lineage Cell Therapeutics (LCTX) Shares Issued (2016 - 2025)
Historic Shares Issued for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $487000.0.
- Lineage Cell Therapeutics' Shares Issued rose 477000.0% to $487000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $487000.0, marking a year-over-year increase of 10772.04%. This contributed to the annual value of $229000.0 for FY2024, which is 16022.73% up from last year.
- Per Lineage Cell Therapeutics' latest filing, its Shares Issued stood at $487000.0 for Q3 2025, which was up 477000.0% from $10000.0 recorded in Q3 2024.
- In the past 5 years, Lineage Cell Therapeutics' Shares Issued ranged from a high of $33.1 million in Q2 2021 and a low of -$6.5 million during Q4 2023
- Moreover, its 5-year median value for Shares Issued was $379000.0 (2022), whereas its average is $3.9 million.
- Per our database at Business Quant, Lineage Cell Therapeutics' Shares Issued plummeted by 9997.28% in 2022 and then skyrocketed by 6365555.56% in 2023.
- Over the past 5 years, Lineage Cell Therapeutics' Shares Issued (Quarter) stood at $124000.0 in 2021, then skyrocketed by 386.29% to $603000.0 in 2022, then plummeted by 1184.08% to -$6.5 million in 2023, then skyrocketed by 100.15% to $10000.0 in 2024, then soared by 4770.0% to $487000.0 in 2025.
- Its last three reported values are $487000.0 in Q3 2025, $10000.0 for Q3 2024, and $87000.0 during Q2 2024.